<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JKMS</journal-id>
      <journal-title-group>
        <journal-title>Journal of Korean Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8934</issn>
      <issn pub-type="epub">1598-6357</issn>
      <publisher>
        <publisher-name>The Korean Academy of Medical Sciences</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">16361802</article-id>
      <article-id pub-id-type="pmc">2779324</article-id>
      <article-id pub-id-type="doi">10.3346/jkms.2005.20.6.947</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Somatostatin for Postoperative Chylothorax after Surgery for Children with Congenital Heart Disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lim</surname>
            <given-names>Kyoung Ah</given-names>
          </name>
          <xref ref-type="aff" rid="A1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Sung Hye</given-names>
          </name>
          <xref ref-type="aff" rid="A2">*</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Huh</surname>
            <given-names>June</given-names>
          </name>
          <xref ref-type="aff" rid="A2">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kang</surname>
            <given-names>I-Seok</given-names>
          </name>
          <xref ref-type="aff" rid="A2">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Heung Jae</given-names>
          </name>
          <xref ref-type="aff" rid="A2">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jun</surname>
            <given-names>Tae-Gook</given-names>
          </name>
          <xref ref-type="aff" rid="A3">&#x2020;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Pyo Won</given-names>
          </name>
          <xref ref-type="aff" rid="A3">&#x2020;</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">Department of Pediatrics, Pochon CHA University College of Medicine, Pochon, Korea.</aff>
      <aff id="A2"><label>*</label>Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>
      <aff id="A3"><label>&#x2020;</label>Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Address for correspondence: June Huh, M.D. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. Tel: +82.2-3410-3526, Fax: +82.2-3410-0043, <email>herzhuh@smc.samsung.co.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2005</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>12</month>
        <year>2005</year>
      </pub-date>
      <volume>20</volume>
      <issue>6</issue>
      <fpage>947</fpage>
      <lpage>951</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>3</month>
          <year>2005</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>6</month>
          <year>2005</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2005 The Korean Academy of Medical Sciences</copyright-statement>
        <copyright-year>2005</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Chylothorax is a rare but serious postoperative condition with a high rate of morbidity that may lead to death of children with congenital heart disease. Here we reviewed nine consecutive cases with chylothorax in infants and children following cardiac surgery from March 2002 to February 2003. Somatostatin was added to conservative treatment proctocol to increase effectiveness of therapy in all cases. The duration of somatostatin therapy varied from 7 to 32 days. All cases of chylothorax were successfully treated with intravenous infusion of somatostatin as an adjunctive treatment. Even though two cases showed rebound phenomena, we avoided any surgical procedure in the nine patients who treated with conservative management combined with somatostatin. No significant side effects of somatostatin were observed. It seems that somatostatin is effective, noninvasive and safe therapeutic modality. It can be used as an adjunctive treatment to conservative management to control postoperative chylothorax in children with congenital heart disease.</p>
      </abstract>
      <kwd-group>
        <kwd>Somatostatin</kwd>
        <kwd>Chylothorax</kwd>
        <kwd>Heart Defect, Congenital</kwd>
        <kwd>Postoperative Complications</kwd>
        <kwd>Child</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Postoperative chylothorax is a rare complication in children who have undergone cardiac surgery for congenital heart disease. When it occurs, it can contribute to patient's morbidity or mortality. The general treatment strategy of postoperative chylothorax is conservative, but surgical reintervention may be indicated in refractory cases. Lymphatic duct ligation or pleurodesis has been considered as the proper surgical intervention (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). With these surgical treatments, however, problems still remain, and the results are not always satisfactory. Furthermore, persistent chylothorax may cause the additional risks to the already compromised patient due to reopening the chest for lymphostasis. Therefore, a noninvasive treatment for postoperative chylothorax would be better for the high-risk patients with congenital heart defect. Over the last years, an additional conservative treatment option with somatostatin has been introduced as a new modality for treatment of postoperative chylothorax (<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>). Thus far, the results have been mostly reported in the literature as individual case reports on children.</p>
      <p>In this study, we report our experience in the management of postoperative chylothorax, with emphasis on the efficacy of somatostatin therapy in infant and children with chylothorax after cardiac surgery.</p>
    </sec>
    <sec sec-type="methods">
      <title>MATERIALS AND METHODS</title>
      <p>From March 2002 to February 2003, nine patients developed chylothorax following operations for treatment of congenital cardiovascular disease at Samsung Medical Center. Chylothorax was diagnosed based on the presence of pleural fluid containing at least one of the following three characteristics: 1) milky appearance; 2) pleural fluid triglyceride levels greater than 110 mg/mL; 3) lymphocytic predominance in the fluid cellular component along with sterile cultures (<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>).</p>
      <p>The conventional treatment had been undertaken upon recognition of chylothorax in all patients initially. The conventional treatment consisted of drainage of the pleural space by thoracentesis or tube thoracostomy, total parenteral nutrition, enteric rest or diet manipulation such as oral fat intake restricted to medium-chain triglycerides. If the amount of chylous leakage increased in 2 or 3 consecutive days after the conventional treatment, then intravenous somatostatin infusion was instituted. The initial starting dose was 3.5 &#xB5;g/kg/hr and dosage was increased in a stepwise fashion up to 5, 7, and 10 &#xB5;g/kg/hr and with a maximum dosage of 15 &#xB5;g/kg/hr. Calories, electrolytes, proteins and clotting factors were monitored and replaced as necessary. Those patients submitted to cavo-pulmonary procedure (Fontan operation) were also treated with diuretics, inotropes and vasodilators in order to reduce systemic venous pressure overload. The duration of somatostatin administration was dependent on the patient's response. After cessation of the chylous leakage and resumption of normal dietary habits, we initiated a tapering of somatostatin administration by halving the dosage every day over a 3-day period. Side effects of somatostatin such as hypotension, loose stool, and glucose instability were carefully monitored on a regular basis.</p>
      <p>All results are represented as means or median values with ranges.</p>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <p><xref ref-type="table" rid="T1">Table 1</xref> shows details of patient, age at time of surgery, the cardiac diagnosis, the type of operation performed, interval to diagnosis of chylothorax after cardiac operation and the maximal drainage volume per day. The patients ranged in age from 1 week to 4 yr old. They were diagnosed of chylothorax between postoperative day 2 and day 16. The maximal daily volume of drainage ranged from 10 to 127 mL/kg per day. Only one patient (patient 1) experienced chylopericardium combined with chylothorax.</p>
      <p><xref ref-type="table" rid="T2">Table 2</xref> indicates result of the treatment and the final outcome for each case. The duration of somatostatin therapy varied from 7 to 32 days with a median duration of 18 days. A decrease in drainage was observed at an average of 3.1 days after the initiation of somatostatin, as the dose of somatostatin had increased enough to produce an effect (<xref ref-type="fig" rid="F1">Fig. 1</xref>). All cases of chylothorax were successfully treated with conservative management combined with intravenous infusion of somatostatin. The median duration to reduce to 5 mL/kg per day of lymph drainage was 5 days (range 1 to 25 days). In patient 6 and patient 9, a rebound phenomenon of chylothorax was noted upon the reduction of somatostatin therapy, but the rebound effusion responded promptly when the dose of somatostatin was boosted (<xref ref-type="fig" rid="F2">Fig. 2</xref>). No increase in drainage was observed when their normal diet was resumed. All nine patients had recovered completely from postoperative chylothorax by the use of somatostatin, and could avoid any invasive surgical interventions.</p>
      <sec>
        <title>Patient 4</title>
        <p>A 3-yr-old girl with a double outlet right ventricle and atrioventricular septal defect required a Fontan operation. The postoperative course was complicated by chylothorax after 3 days of operation. Her chylothorax was managed with total parenteral nutrition and diet modification firstly. However pleural effusion persisted. The patient was started on somatostatin continuous infusion of 3.5 &#xB5;g/kg/hr when her pleural fluid losses were still 510 mL/day. But the chylous leak was increased for the next 8 days. At that time, her cardiac catheterization showed near complete occlusion of superior vena cava with large thrombus. Because the volume of daily leakage was up to 1,000 mL and the patient was in an unstable condition, we decided to attempt an exceptional increase in the somatostatin dose at 15 &#xB5;g/kg/hr before considering the surgical management. She had a distinguished course of treatment. The volume of daily chylous leakage was decreased dramatically. Chylothorax ceased completely on day 35 without any surgical intervention. In this patient, superior vena cava syndrome was considered a contributing factor for the prolonged chylous drainage, but the high dose somatostatin infusion was tolerated for 21 days without any apparent side effects (<xref ref-type="fig" rid="F3">Fig. 3</xref>).</p>
      </sec>
      <sec>
        <title>Patient 9</title>
        <p>10-day-old girl born with transposition of great arteries and ventricular septal defect underwent arterial switch operation and closure of ventricular septal defect. On postoperative day 9, she had second operation for wound debriment and repair of surgical wound. After that day, drainage from chest tube became large up to 300 mL/day, when her chylothorax was confirmed. Her chylous drainage was persistent after conservative managements, so we added infusion of somatostatin. Her chylous leakage decreased to 40 mL/day by postoperative day 32. She developed loose stool for 2 days during the infusion of somatostatin, but the diarrhea spontaneously resolved. Aside from this, there were no apparent adverse effects of the somatostatin.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Chylothorax is a rare, but potentially serious complication of pediatric cardiac operations. It was estimated to occur at an incidence of 0.25% to 0.8% following cardiovascular procedures (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). The standard treatment for postoperative chylothorax includes conservative therapy with pleural space evacuation, enteric rest or fat-free nutrition, and total parenteral nutrition (<xref ref-type="bibr" rid="B11">11</xref>). If this is not successful, operative treatment such as pleurodesis, ligation of the thoracic duct and pleuroperitoneal shunt is indicated (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). However, these surgical treatments have some limitations. Pleurodesis is a painful procedure and the long-term results can vary. Ligation of the thoracic duct may fail as a result of anatomic variations of the thoracic duct or due to a failure for identifying the chylous leakage sites (<xref ref-type="bibr" rid="B6">6</xref>).</p>
      <p>There have been several anecdotal reports in the literature related to using somatostatin for treating chylothorax as a complication of thoracic procedures in adults (<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>). Somatostatin is a peptide hormone that acts as a neurohormone as well as a paracrine agent, and it is present in the central nervous system, gastrointestinal tract and pancreas (<xref ref-type="bibr" rid="B14">14</xref>). The exact mechanisms involved for the drying effect of somatostatin on lymphatic leakage are not wholly understood. The effectiveness of somatostatin may be due to its ability to decrease the hepatic venous pressure gradient, to decrease the intestinal absorption of fats, to decrease the triglyceride concentration in the thoracic duct and to attenuate splanchnic blood flow (<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>). In addition, it could be that the lymphatic vessels contain somatostatin receptors, like the blood vessels in the splanchnic area, and that their constriction reduces the lymph production (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>).</p>
      <p>In 1998, Rimensberger et al. (<xref ref-type="bibr" rid="B20">20</xref>) reported the successful use of somatostatin in children to control increasing chylous drainage under conservative treatment. In addition, the authors described several pediatric cases of postoperative chylothorax that were treated with somatostatin (<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>). In our study, 3 patients underwent surgical procedure for their congenital heart disease during the neonatal period. In our cases, no serious complications associated with unabated chylous drainage were encountered, which is in contrast to the previous reports (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). This is probably due to the prompt use of intravenous somatostatin after the diagnosis of chylothorax during the postoperative period.</p>
      <p>Opinions vary in the literature regarding the appropriate dose and type of administration for somatostatin for children with postoperative chylothorax. The starting dose was 3.5 &#xB5;g/kg/hr according to the case report of Rimensberger et al. (<xref ref-type="bibr" rid="B20">20</xref>). Buettiker et al. suggest that chyle production began cessation at a dose of 10 &#xB5;g/kg/hr, but they also tried increasing the dose up to 12 &#xB5;g/kg/hr for chylothorax refractory to the conventional dose (<xref ref-type="bibr" rid="B21">21</xref>). In our study, we increased the dosage of somatostatin up to 15 &#xB5;g/kg/hr in one case without observing any serious side effects. Somatostatin is currently used for the therapy of diverse pediatric diseases such as acromegaly, intractable diarrhea and gastrointestinal bleeding (<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B29">29</xref>). Because this therapy is still experimental, further studies that take into consideration the duration and tolerable dosages are necessary to assess the safety of its administration in children.</p>
      <p>Superior vena cava thrombosis is also well known to be a risk factor for the failure of non-operative management of chylothorax (<xref ref-type="bibr" rid="B1">1</xref>). It is usually recommended that such patients be considered for earlier operative intervention when this complication is associated with chylothorax. In our case, however, the patient's poor general condition led us to attempt somatostatin trial before any invasive steps. The satisfactory outcome in this patient may be speculated as the results of somatostatin and/or the development of collateral lymphatic channels.</p>
      <p>The side effect of somatostatin is primarily related to the suppressed actions of gastrointestinal motility and secretion, and this includes hypotension, loose stool, malabsorption, nausea, flatulence, liver dysfunction and hyperglycemia (<xref ref-type="bibr" rid="B15">15</xref>). In all 9 patients, no significant side effects were observed that necessitated medical intervention or discontinuation of somatostatin.</p>
      <p>The results of our case series are suggesting the value and safety of somatostatin in pediatric patients with postoperative chylothorax. The continuous infusion of somatostatin may be of particular benefit if the patient is in a poor general condition, and additional risks may be introduced with repeated surgery. A larger prospective study needs to be undertaken to verify our investigations.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bond</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Guzzetta</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Randolph</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Management of pediatric postoperative chylothorax</article-title>
          <source>Ann Thorac Surg</source>
          <year>1993</year>
          <volume>56</volume>
          <fpage>469</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="pmid">8379718</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Shum-Tim</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dobell</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Tchervenkov</surname>
              <given-names>CI</given-names>
            </name>
          </person-group>
          <article-title>The management of chylothorax/chylopericardium following pediatric cardiac surgery: a 10-year experience</article-title>
          <source>J Card Surg</source>
          <year>1995</year>
          <volume>10</volume>
          <fpage>302</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="pmid">7549187</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collard</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Laterre</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Boemer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Reynaert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ponlot</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Conservative treatment of postsurgical lymphatic leaks with somatostatin-14</article-title>
          <source>Chest</source>
          <year>2000</year>
          <volume>117</volume>
          <fpage>902</fpage>
          <lpage>905</lpage>
          <pub-id pub-id-type="pmid">10713026</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Shumway</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Conservative management of postoperative chylothorax using somatostatin</article-title>
          <source>Ann Thorac Surg</source>
          <year>2000</year>
          <volume>69</volume>
          <fpage>1944</fpage>
          <lpage>1945</lpage>
          <pub-id pub-id-type="pmid">10892958</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ulibarri</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fuentes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mancha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aramendia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin</article-title>
          <source>Lancet</source>
          <year>1990</year>
          <volume>336</volume>
          <fpage>258</fpage>
          <pub-id pub-id-type="pmid">1973814</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferguson</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Skinner</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Current concepts in the management of postoperative chylothorax</article-title>
          <source>Ann Thorac Surg</source>
          <year>1985</year>
          <volume>40</volume>
          <fpage>542</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="pmid">4074001</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higgins</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Reinke</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
          <article-title>Postoperative chylothorax in children with congenital heart disease. Clinical and roentgenographic features</article-title>
          <source>Radiology</source>
          <year>1976</year>
          <volume>119</volume>
          <fpage>409</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">1265272</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Staats</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Ellefson</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Budahn</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Dines</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>UB</given-names>
            </name>
            <name>
              <surname>Offord</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The lipoprotein profile of chylous and nonchylous pleural effusions</article-title>
          <source>Mayo Clin Proc</source>
          <year>1980</year>
          <volume>55</volume>
          <fpage>700</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="pmid">7442324</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higgins</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Chylothorax after surgery for congenital heart disease</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <year>1971</year>
          <volume>61</volume>
          <fpage>411</fpage>
          <lpage>418</lpage>
          <pub-id pub-id-type="pmid">5545585</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pedra</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Pedra</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Fontes</surname>
              <given-names>VF</given-names>
            </name>
            <name>
              <surname>Santana</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Paulista</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title>Chylothorax after surgery for congenital heart disease in children</article-title>
          <source>Cardiol Young</source>
          <year>1998</year>
          <volume>8</volume>
          <fpage>199</fpage>
          <lpage>204</lpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>van Heeckeren</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Spector</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Blumer</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Management of nutritional and infectious complications of postoperative chylothorax in children</article-title>
          <source>J Pediatr Surg</source>
          <year>1991</year>
          <volume>26</volume>
          <fpage>1169</fpage>
          <lpage>1174</lpage>
          <pub-id pub-id-type="pmid">1779326</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selle</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>WH</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Chylothorax: Indications for surgery</article-title>
          <source>Ann Surg</source>
          <year>1973</year>
          <volume>177</volume>
          <fpage>245</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="pmid">4698540</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolff</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Silen</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kokoska</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Rodgers</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Treatment of refractory chylothorax with externalized pleuroperitoneal shunts in children</article-title>
          <source>Ann Thorac Surg</source>
          <year>1999</year>
          <volume>68</volume>
          <fpage>1053</fpage>
          <lpage>1057</lpage>
          <pub-id pub-id-type="pmid">10510006</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Davis</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Granner</surname>
              <given-names>DK</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Gilman</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Hardman</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Limbird</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Molionoff</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Ruddon</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas</article-title>
          <source>Goodman and Gilman's the pharmacological basis of therapeutics</source>
          <year>1996</year>
          <edition>9th edn</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Pergamon press</publisher-name>
          <fpage>1512</fpage>
          <lpage>1513</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grosman</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide</article-title>
          <source>Am J Gastroenterol</source>
          <year>1990</year>
          <volume>85</volume>
          <fpage>1061</fpage>
          <lpage>1072</lpage>
          <pub-id pub-id-type="pmid">1975156</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sonnenberg</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Perruchoud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Burckhardt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gyr</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects</article-title>
          <source>Gastroenterology</source>
          <year>1981</year>
          <volume>80</volume>
          <fpage>526</fpage>
          <lpage>532</lpage>
          <pub-id pub-id-type="pmid">6108898</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakabayashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sagara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Usukura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshimitsu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Seta</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yanase</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kawato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hiraiwa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sakato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs</article-title>
          <source>Diabetes</source>
          <year>1981</year>
          <volume>30</volume>
          <fpage>440</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="pmid">6112179</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leibovitch</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mor</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Golomb</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ramon</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The diagnosis and management of postoperative chylous ascites</article-title>
          <source>J Urol</source>
          <year>2002</year>
          <volume>167</volume>
          <fpage>449</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">11792897</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scarpignato</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pelosini</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety</article-title>
          <source>Digestion</source>
          <year>1999</year>
          <volume>60</volume>
          <issue>Suppl 3</issue>
          <fpage>1</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">10567784</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rimensberger</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Muller-Schenker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kalangos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beghetti</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Treatment of a persistent postoperative chylothorax with somatostatin</article-title>
          <source>Ann Thorac Surg</source>
          <year>1998</year>
          <volume>66</volume>
          <fpage>253</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="pmid">9692478</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buettiker</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hug</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Burger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Baenziger</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Somatostatin: a new therapeutic option for the treatment of chylothorax</article-title>
          <source>Intensive Care Med</source>
          <year>2001</year>
          <volume>27</volume>
          <fpage>1083</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="pmid">11497142</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pettitt</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Caspi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Borne</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Treatment of persistent chylothorax after Norwood procedure with somatostatin</article-title>
          <source>Ann Thorac Surg</source>
          <year>2002</year>
          <volume>73</volume>
          <fpage>977</fpage>
          <lpage>979</lpage>
          <pub-id pub-id-type="pmid">11899219</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JU</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>YJ</given-names>
            </name>
          </person-group>
          <article-title>Conservative management of postoperative chylothorax using octreotide: a case report</article-title>
          <source>Korean J Thorac Cardiovasc Surg</source>
          <year>2005</year>
          <volume>38</volume>
          <fpage>172</fpage>
          <lpage>174</lpage>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhatia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pratap</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Slavik</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum</article-title>
          <source>Arch Dis Child</source>
          <year>2001</year>
          <volume>85</volume>
          <fpage>234</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">11517107</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Nita</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Gastrointestinal bleeding</article-title>
          <source>J Pediatr (Rio J)</source>
          <year>2000</year>
          <volume>76</volume>
          <fpage>S135</fpage>
          <lpage>S146</lpage>
          <pub-id pub-id-type="pmid">14676917</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoeldtke</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Boden</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>O'Dorisio</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Treatment of postprandial hypotension with a somatostatin analogue (SMS201-995)</article-title>
          <source>Am J Med</source>
          <year>1986</year>
          <volume>81</volume>
          <fpage>83</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">2879451</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunziker</surname>
              <given-names>UA</given-names>
            </name>
            <name>
              <surname>Superti-Furga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zachmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Del Pozo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Shmerling</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Prader</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Effects of the long-acting somatostatin analogue SMS 201-995 in an infant with intractable diarrhea</article-title>
          <source>Helv Paediatr Acta</source>
          <year>1988</year>
          <volume>43</volume>
          <fpage>103</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">2844705</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jenkins</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Drug therapy for non-variceal upper gastrointestinal bleeding. Assessment of options</article-title>
          <source>Digestion</source>
          <year>1999</year>
          <volume>60</volume>
          <issue>Suppl 3</issue>
          <fpage>39</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">10567788</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yachha</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Chetri</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lal</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Management of portal hypertension</article-title>
          <source>Indian J Pediatr</source>
          <year>2002</year>
          <volume>69</volume>
          <fpage>809</fpage>
          <lpage>813</lpage>
          <pub-id pub-id-type="pmid">12420915</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Clinical course of patient number 3.</p>
      </caption>
      <graphic xlink:href="jkms-20-947-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Clinical course of patient number 6.</p>
      </caption>
      <graphic xlink:href="jkms-20-947-g002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Fig. 3</label>
      <caption>
        <p>Clinical course of patient number 4.</p>
      </caption>
      <graphic xlink:href="jkms-20-947-g003"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Characteristics of patients with chylothorax</p>
      </caption>
      <graphic xlink:href="jkms-20-947-i001"/>
      <table-wrap-foot>
        <fn>
          <p>ASD, atrial septal defect; ASO, arterial switch operation; AVSD, atrioventricular septal defect; DILV, double inlet left ventricle; DORV, double outlet right ventricle; IAA, interruption of aortic arch; MAPCA, major aortopulmonary collateral arteries; PA, pulmonary atresia; PDA, patent ductus arteriosus; POD, post operative day; PS, pulmonary stenosis; RMBT, right modified Blalock-Taussig shunt; SV, single ventricle; TAPVR, total anomalous pulmonary venous return; TGA, transposition of great arteries; VSD, ventricular septal defect.</p>
          <p><sup>*</sup>, maximal daily drainage (mL/kg/day).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T2" position="float">
      <label>Table 2</label>
      <caption>
        <p>Outcomes of patients with somatostatin therapy</p>
      </caption>
      <graphic xlink:href="jkms-20-947-i002"/>
      <table-wrap-foot>
        <fn>
          <p>Duration 1, duration of somatostatin therapy (day); Duration 2, duration to reduction of chylous leakage to 5 mL/kg/day (day); CM, conservative management.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
